Charles River Laboratories Strengthens Operations with Global Corporate Senior Vice President Appointments

Business Wire, Nov 2, 2007

WILMINGTON, Mass. -- Charles River Laboratories International, Inc. (NYSE: CRL) today announced the promotions of three industry veterans, including: Brian Bathgate, Ph.D., to Corporate Senior Vice President and President, European Preclinical Services, Jorg Geller, D.V.M., Ph.D., to Corporate Senior Vice President, Japanese Operations and Global Large Research Model and Avian Operations and Christopher Perkin to Corporate Senior Vice President and President, Canadian Preclinical Services. These promotions are part of an ongoing effort to strengthen the Company's global leadership, enhance the implementation of customer-focused strategies and improve operational effectiveness.

"The managerial expertise and impressive track records of Brian, Jorg and Chris have played an integral role in our Company's growth and success. Their ability to anticipate and exceed customer expectations enables us to remain steadfast in our commitment to providing superior products and services," said James C. Foster, Chairman, President and Chief Executive Officer of Charles River Laboratories.

The promotions are testament to Charles River's commitment to cultivate its leaders from within the organization.

* Brian Bathgate joined Charles River in December 2004, following the Inveresk merger, and was named Corporate Vice President and President, European Preclinical Services. Since joining the organization, Dr. Bathgate has assumed responsibility for Charles River's global biopharmaceutical business, as well as the Company's drug discovery and development services in Ireland. In addition, Dr. Bathgate is also responsible for the Phase I clinical business in Edinburgh. Under his direction, these businesses have achieved outstanding and consistent levels of performance.

* Dr. Geller joined Charles River Germany in 1986 overseeing its research model production operations. In 1997, Dr. Geller became responsible for Charles River's Avian operations on a global basis. In 2004, Dr. Geller was given responsibility for Charles River's global large research model operations. In his expanded role, Dr. Geller will also assume responsibility for Charles River Japan, where his leadership talents will be extremely valuable in this competitive market.

* Christopher Perkin also joined Charles River in 2004, following the Inveresk merger, and was named Corporate Vice President and President, Canadian Preclinical Services. Mr. Perkin manages Charles River's largest facility, which is about to be expanded. In addition, he oversees the preclinical services operations in Pennsylvania, creating a strong link between these closely aligned businesses. Under his direction, Charles River also established preclinical operations in China this year.

About Charles River Laboratories

Charles River Laboratories based in Wilmington, Massachusetts, partners with global pharmaceutical and biotechnology companies, government agencies and leading academic institutions to advance the drug discovery and development process, bringing drugs to market faster and more efficiently. Charles River's 8,300 employees serve clients worldwide. For more information on Charles River, visit our website at www.criver.com.